Medivir AB as previously announced, Erik Björk will leave the role as Medivir’s CFO. Lotta Ferm will assume the role as interim CFO as of March 1st.
HUDDINGE, Sweden, Feb. 18, 2019 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) as previously announced, Erik Björk will leave the role as Medivir’s CFO. Lotta Ferm will assume the role as interim CFO as of March 1st. Recruitment of a permanent CFO is ongoing.
For further information, please contact:
Uli Hacksell
CEO
Medivir AB
mobile: +46 (0)73 125 0615.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir’s business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. http://www.medivir.com/.
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/lotta-ferm-appointed-as-interim-cfo-at-medivir,c2743477
The following files are available for download:
| Press release (PDF) |
View original content:http://www.prnewswire.com/news-releases/lotta-ferm-appointed-as-interim-cfo-at-medivir-300797139.html
SOURCE Medivir
Company Codes: Stockholm:MVIRB, Berlin:MVR, Bloomberg:MVIRB@SS, ISIN:SE0000273294, LSE:0GP7, OTC-PINK:MVRBF, RICS:MVIRB.ST, Dusseldorf:MVR, Frankfurt:MVR, Munich:MVR, Stuttgart:MVR
